🔗 Share this article

The first new treatments for gonorrhoea in a generation are being described as a "major milestone" in the effort against drug-resistant strains of the bacteria, according to health experts.

A Worldwide Challenge

The sexually transmitted infection are increasing worldwide, with data suggesting in excess of 82 million infections per year. Notably increased rates are reported in the African continent and nations within the World Health Organization's Western Pacific region, which spans from Mongolia and China to New Zealand. Within England, cases have hit a historical peak, while infection numbers across Europe in 2023 were three times higher compared to those in 2014.

“The clearance of fresh medications for gonorrhoea is an important and timely step in the reality of growing infection rates, escalating drug resistance and the highly restricted therapeutic options at this time.”

Health officials are particularly alarmed about the surge in antibiotic-resistant strains. The WHO has classified it as a "critical concern". Ongoing monitoring found that resistance to standard treatments like ceftriaxone and cefixime jumped significantly between 2022 and 2024.

Two New Treatment Options Gain Authorization

Zoliflodacin, also known as Nuzolvence, was authorized by the US FDA in recent days for combating gonorrhoea. This STI can lead to significant complications, including infertility. Experts anticipate that targeted use of this new drug will help delay the development of resistance.

Another new antibiotic, developed by the drugmaker GSK, gained clearance in concurrent days. This medication, which is employed against UTIs, was proven in research to be successful in treating antibiotic-resistant forms of the gonorrhoea bacteria.

A Unique Approach to Creation

This new treatment emerged from a new, not-for-profit approach for medication research. The charitable organization GARDP partnered with the pharmaceutical company its industry partner to bring it to fruition.

“This approval marks a huge turning point in the treatment of highly resistant gonorrhoea, which up to this point has been evolving faster than our drug pipeline.”

Clinical Trial Results and Global Access

As per findings detailed in a major medical journal, the new drug cured more than 90% of cases of the STI. This establishes an similar efficacy with the existing first-line therapy, which uses a dual-drug approach. The trial enrolled hundreds of participants from various regions including Belgium, the Netherlands, South Africa, Thailand and the US.

Through the arrangement of its development partnership, GARDP has the rights to make available and distribute the drug in numerous developing nations.

Medical professionals on the front lines have voiced optimism. Having a one-pill regimen such as this is seen as a "game-changer" for managing the epidemic. This is viewed as essential to lessen the impact of the illness for people and to stop the proliferation of highly drug-resistant gonorrhoea around the world.